Last reviewed · How we verify
Desflurane
Desflurane, marketed by the National Cancer Institute in Egypt, holds a position in the anesthetic agent market with a key composition patent expiring in 2028. Its key strength lies in its rapid onset and offset of action, which enhances surgical efficiency. The primary risk is the potential increase in competition post-patent expiry in 2028.
At a glance
| Generic name | Desflurane |
|---|---|
| Also known as | Suprane, group D |
| Sponsor | National Cancer Institute, Egypt |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Desflurane vs. Propofol for Cardiac Anesthesia (PHASE3)
- Comparison of Postoperative QoR-15 Scores Between Desflurane and Remimazolam in Lumbar Fusion Surgery (NA)
- Effect of Propofol and Desflurane on Nucleic Acid of Liver Circulating Tumor (PHASE2)
- Desflurane and Sevoflurane in Pediatrics With Elevated Liver Enzymes (NA)
- The Effect of Desflurane on Postopertative Cognitive Dysfunction (PHASE4)
- Comparison of Desflurane With Sevoflurane for School-age Children in Postoperative Cognitive Function (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Desflurane CI brief — competitive landscape report
- Desflurane updates RSS · CI watch RSS
- National Cancer Institute, Egypt portfolio CI